Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism
New Variants Also Make SARS-CoV2 A Moving Target
Executive Summary
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
You may also be interested in...
Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.
Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.